Stockscreener 앱 받기
4.65
1.97%
0.09
시간 외 거래:
4.50
-0.15
-3.23%
전일 마감가:
$4.56
열려 있는:
$4.57
하루 거래량:
194.94K
Relative Volume:
0.09
시가총액:
$6.94M
수익:
$8.62M
순이익/손실:
$-6.15M
주가수익비율:
-0.4216
EPS:
-11.03
순현금흐름:
$-5.32M
1주 성능:
-18.92%
1개월 성능:
+68.90%
6개월 성능:
+4.26%
1년 성능:
-27.02%
1일 변동 폭
$4.1744
$4.80
1주일 범위
$4.1744
$5.59
52주 변동 폭
$1.94
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
명칭
Evoke Pharma Inc
전화
858-345-1494
주소
420 STEVENS AVENUE, SOLANA BEACH, CA
EVOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
4.65 | 8.56M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
147.37 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.53 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.31 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.12 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2019-03-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-08 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-10-19 | 재개 | FBR & Co. | Buy |
| 2017-03-16 | 재확인 | Rodman & Renshaw | Buy |
| 2017-01-30 | 업그레이드 | Laidlaw | Neutral → Buy |
| 2017-01-05 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2016-12-23 | 재확인 | Rodman & Renshaw | Neutral |
| 2016-07-19 | 재확인 | FBR Capital | Outperform |
| 2016-07-19 | 다운그레이드 | Noble Financial | Buy → Hold |
| 2016-07-18 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2016-03-16 | 개시 | Northland Capital | Outperform |
| 2016-03-14 | 재확인 | Ascendiant Capital Markets | Buy |
| 2016-02-17 | 재개 | FBR Capital | Outperform |
| 2014-12-03 | 재확인 | MLV & Co | Buy |
| 2014-11-07 | 개시 | MLV & Co | Buy |
| 2014-04-22 | 개시 | Laidlaw | Buy |
| 2013-11-19 | 개시 | Aegis Capital | Buy |
모두보기
Evoke Pharma Inc 주식(EVOK)의 최신 뉴스
What analysts say about Evoke Pharma Inc. stockExceptional earning trajectories - Autocar Professional
Is Evoke Pharma Inc. a good long term investmentOutstanding stock performance - PrintWeekIndia
What drives Evoke Pharma Inc. stock priceFree Risk Assessment Services - jammulinksnews.com
What drives bioAffinity Technologies Inc. Equity Warrant stock priceRemarkable growth - Autocar Professional
Evoke Pharma Inc. Stock Analysis and ForecastConsistent double returns - jammulinksnews.com
What analysts say about PSQH stockFree Stock Market Forecast Reports - Jammu Links News
MGP Ingredients Inc. Stock Analysis and ForecastTriple-digit returns - jammulinksnews.com
Evoke Pharma Shares Jump 50% Following Patent Approval for GIMOTI - MSN
Why did EVOK's Q4 2024 earnings beat forecasts? - AInvest
How Evoke Pharma Inc. stock performs during market volatilityReal Time Breakout Tracking - Newser
Why Evoke Pharma Inc. stock attracts strong analyst attentionStrong Buy Recommendations - Newser
What makes Evoke Pharma Inc. stock price move sharplyVerified Chart Patterns - Newser
Small Cap Stocks Worth Watching – July 9th - Defense World
Promising Pharmaceutical Stocks To Watch Now – July 9th - Defense World
Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In - NewsBreak: Local News & Alerts
Evoke Pharma skyrockets on patent allowance for diabetes nasal spray drug - Mugglehead Magazine
Evoke Pharma receives patent allowance for gastroparesis nasal spray By Investing.com - Investing.com South Africa
Evoke Pharma (EVOK) Soars 162.78% on Patent Extension - AInvest
Crude Oil Moves Higher; RxSight Shares Plunge - Benzinga
Evoke Pharma shares surge 24.57% intraday after receiving Notice of Allowance for U.S. patent application for GIMOTI®. - AInvest
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On? - Benzinga
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga
Evoke Pharma Shares Soar After Patent Allowance for Gastroparesis Treatment - MarketScreener
Evoke Pharma (EVOK) Stock Soars Following Positive Patent News - Stocks Telegraph
Evoke Pharma: Is the Bounce Back Real? - StocksToTrade
EVOK Stock: Boom or Bust? - timothysykes.com
Evoke Pharma (EVOK) Secures New Patent Approval for GIMOTI | EVO - GuruFocus
Evoke Pharma stock soars after receiving patent allowance for GIMOTI By Investing.com - Investing.com South Africa
Evoke Pharma stock soars after receiving patent allowance for GIMOTI - Investing.com
Evoke Pharma (EVOK) Secures Key Patent for Gastroparesis Treatment | EVOK Stock News - GuruFocus
Pre-market Movers: CLDI, BMGL, PROK, RXST... - RTTNews
Evoke Pharma Receives Notice of Allowance for U.S. Patent Applic - GuruFocus
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 | EVOK Stock News - GuruFocus
Evoke Pharma, Inc. Receives Patent Allowance for GIMOTI® in Treatment of Gastroparesis Symptoms - Quiver Quantitative
Evoke Pharma Receives Notice of Allowance for U.S. Patent - GlobeNewswire
Major Patent Win: GIMOTI Locks Down 6 More Years of Exclusivity for Revolutionary Gastroparesis Spray - Stock Titan
Evoke Pharma Secures Patent for GIMOTI Treatment - TipRanks
GILT lands >$22M Tier-One satellite orders, boosts multi-orbit momentum | EVOK SEC FilingForm 8-K - Stock Titan
Evoke Pharma Inc (EVOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.68%
자본화:
|
볼륨(24시간):